Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892538 | 0.99 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL8804417 | 0.92 | EDNRB (0.86) | EDNRBEDNRA | |
| SCHEMBL795650 | 0.91 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL7206507 | 0.89 | EDNRB (0.83) | EDNRBEDNRA | |
| SCHEMBL8659586 | 0.88 | EDNRA (0.85) | EDNRBEDNRA | |
| SCHEMBL8802029 | 0.88 | EDNRB (0.84) | EDNRBEDNRA | |
| SCHEMBL8660578 | 0.86 | EDNRB (0.90) | EDNRBEDNRA | |
| SCHEMBL8659093 | 0.84 | EDNRB (0.81) | EDNRBEDNRA | |
| SCHEMBL8801607 | 0.84 | EDNRB (0.84) | EDNRBEDNRA | |
| SCHEMBL8662305 | 0.84 | EDNRB (0.84) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | DOOLEY DAVID JAMES (US) | 2003-12-18 | — | — | US | claimed |
| US-9096703-B2 | Non-fouling, anti-microbial, anti-thrombogenic graft-from compositions | SEMPRUS BIOSCIENCES CORPORATION (US) | 2015-08-04 | — | — | US | disclosed |
| US-8632838-B2 | Articles having non-fouling surfaces and processes for preparing the same including pretreatment of articles | SEMPRUS BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| US-8574660-B2 | Articles having non-fouling surfaces and processes for preparing the same without altering bulk physical properties | SEMPRUS BIOSCIENCES CORPORATION (US) | 2013-11-05 | — | — | US | disclosed |
| US-20080248119-A1 | Production method of drug containing composite particle | HOSOKAWA MICRON CORPORATION (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1868562-A1 | CERAMIC STRUCTURES FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE SUBSTANCES | Altairnano, Inc (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7220430-B2 | Sustained-release preparation and process for producing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20060210634-A1 | Ceramic structures for controlled release of biologically active substances | SPECTRUM PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006096544-A1 | CERAMIC STRUCTURES FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE SUBSTANCES | ALTAIRNANO, INC. (US) | 2006-09-14 | — | — | WO | disclosed |
| US-20050191357-A1 | Method of manufacturing chemical-containing composite particles | HOSOKAWA MICRON CORPORATION (JP) | 2005-09-01 | — | — | US | disclosed |
| EP-1405635-A1 | FUNCTIONAL GRAIN-CONTAINING PREPARATIONS QUICKLY DISINTEGRATED IN THE ORAL CAVITY | TANABE SEIYAKU CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| US-6692769-B1 | Sustained-release particles | TANABE SEIYAKU CO., LTD. (JP) | 2004-02-17 | — | — | US | disclosed |
| US-6692768-B1 | SPHERICAL FINE PARTICLES THAT ARE USEFUL IN THE PRODUCTION OF EASILY-SWALLOWED, CONTROLLED-RELEASE PREPARATIONS HAVING A MEAN PARTICLE SIZE OF 60-200 MU M | TANABE SEIYAKU CO., LTD. (JP) | 2004-02-17 | — | — | US | disclosed |
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | DOOLEY DAVID JAMES (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030012815-A1 | Sustained-release preparation and process for producing the same | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-16 | — | — | US | disclosed |
| EP-1252887-A1 | SUSTAINED-RELEASE PREPARATION AND PROCESS FOR PRODUCING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2002-10-30 | — | — | EP | disclosed |
| US-6395741-B1 | SENSITIVITY TO ENDOTHELIN; UROGENITAL DISORDERS | TANABE SEIYAKU CO., LTD. (JP) | 2002-05-28 | — | — | US | disclosed |
| EP-1125576-A1 | PROCESS FOR PRODUCING SPHERICAL FINE PARTICLES CONTAINING DRUG | TANABE SEIYAKU CO., LTD. (JP) | 2001-08-22 | — | — | EP | disclosed |
| EP-1125586-A1 | SUSTAINED-RELEASE PARTICLES | TANABE SEIYAKU CO., LTD. (JP) | 2001-08-22 | — | — | EP | disclosed |
| EP-1066831-A1 | PREVENTIVES/REMEDIES FOR URINARY DISORDER | TANABE SEIYAKU CO., LTD. (JP) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.